Literature DB >> 7909231

A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.

D Chargelegue1, B T Colvin, C M O'Toole.   

Abstract

OBJECTIVE: To study the humoral immune response to HIV-1 p17 and p24 Gag proteins longitudinally and assess any prognostic value. DESIGN AND METHODS: Fifteen HIV-1 infected patients with haemophilia were asymptomatic at entry to the study in 1986. Each patient was monitored at 6- to 12-month intervals for up to 7 years for p17 and p24 immunoglobulin (Ig)G titres, p17 IgG avidity, total IgG, p24 antigenaemia and CD4 cell counts. Results were correlated with the clinical course.
RESULTS: Between 1986 and 1993, six of the patients developed CD4 cell counts below 200 x 10(6)/l (AIDS patients) while nine retained counts above this level (asymptomatic patients). All AIDS patients were characterized by declining IgG titres to p17 and p24 from 1986-1987 onwards. A reduction in specific p17 and p24 IgG preceded, by at least 3-4 years, the onset of CD4 cell depletion (< 200 x 10(6)/l). These six patients also had significantly lower p17 IgG avidity than the asymptomatic patients throughout the study.
CONCLUSION: Titres of p17 and p24 IgG appeared to alter in the same manner. A progressive reduction in IgG titres and a low p17 IgG avidity were earlier predictors of disease progression than CD4 cell counts or p24 antigenaemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7909231     DOI: 10.1097/00002030-199311002-00017

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection.

Authors:  Catherine Gaudy-Graffin; Gérard Lesage; Isabelle Kousignian; Syria Laperche; Annie Girault; Frédéric Dubois; Alain Goudeau; Francis Barin
Journal:  J Clin Microbiol       Date:  2010-07-07       Impact factor: 5.948

2.  Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques.

Authors:  L Giavedoni; S Ahmad; L Jones; T Yilma
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  Intrapatient sequence variation of the gag gene of human immunodeficiency virus type 1 plasma virions.

Authors:  F K Yoshimura; K Diem; G H Learn; S Riddell; L Corey
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

4.  The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

5.  Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns.

Authors:  Jörg Schüpbach; Martin D Gebhardt; Alexandra U Scherrer; Leslie R Bisset; Christoph Niederhauser; Stephan Regenass; Sabine Yerly; Vincent Aubert; Franziska Suter; Stefan Pfister; Gladys Martinetti; Corinne Andreutti; Thomas Klimkait; Marcel Brandenberger; Huldrych F Günthard
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

Review 6.  Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.

Authors:  Martyn A French; Laila N Abudulai; Sonia Fernandez
Journal:  Vaccines (Basel)       Date:  2013-08-09

7.  Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based Algorithms.

Authors:  Jörg Schüpbach; Christoph Niederhauser; Sabine Yerly; Stephan Regenass; Meri Gorgievski; Vincent Aubert; Diana Ciardo; Thomas Klimkait; Günter Dollenmaier; Corinne Andreutti; Gladys Martinetti; Marcel Brandenberger; Martin D Gebhardt
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.